Paxil Delisting: Will Appellate Case On FDA Patent Listing Role Be Moot?
Executive Summary
TorPharm expects an appeals court case on FDA's role in policing patent listings to remain viable despite GlaxoSmithKline's request that three of the Paxil patents at issue in the lawsuit be delisted
You may also be interested in...
Early Paxil Competitor? FDA Approves Synthon’s Paroxetine 505(b)(2)
Synthon will enter the Paxil market in the fourth quarter with the launch of its paroxetine mesylate product
Early Paxil Competitor? FDA Approves Synthon’s Paroxetine 505(b)(2)
Synthon will enter the Paxil market in the fourth quarter with the launch of its paroxetine mesylate product
GSK Paxil Patent Delistings Open Door For Generic Paroxetine Approvals
GlaxoSmithKline's delisting of three Paxil patents will clear the way for approval of generic versions of the antidepressant, and set up a potential dispute over how 180-day exclusivity will be awarded